Torrent aims to be among first cos to launch Wegovy, Ozempic generics in Brazil
Torrent Pharmaceuticals Ltd, the company’s management on Monday, on Monday, said in a statement on Monday, Novo Nordisk’s weight loss drugs Wegovy and Ozempic’s first generic launches in Brazil since next year.
The GLP-1 (Glucagon-like Peptit-1) compound, sold under the brand Semagluid, Wegovy and Ozempic, will be out of patent in key markets, including India and Brazil in March 2026.
While refusing to share the company’s special plans, Torrent Pharma’s International Business Chairman Sanjay Gupta said that after earnings, Ahmedabad -based drug producer planned generic launches for both Özempic and Wegovy in Brazil.
Gupta, “We are working on both products without giving you more features. And we are trying to be in one of the launch, G Gupta said that the company is working with partners for both drugs.
In Brazil, Ozempic’s market size has declined since 2024 after Wegovy’s launch, Gupta Gupta said. “The current Özempic size fell too much… When he went out of the patent, he would be smaller,” he said.
“Wegovy should come to the market a little later because people haven’t started to file yet… I would be much more gung-ho about Wegovy because the market went and we had the chance to be on the first day,” he said.
As of 2024, Brazil’s Semagluid market is estimated to be $ 581 million. According to Goldman Sachs, a bank, the global market size for GLP-1 is expected to rise to $ 100 billion by 2030.
India, Brazilian driving growth
Torrent Pharma reported that there was an annual 20% increase in net profit in June quarter. La548 Crore is behind double -digit growth in the largest branded markets, India and Brazil.
The company’s income increased by 11% annually La3.178 Crore in accordance with the estimates in June. EBITDA (pre -interest earnings, taxes, depreciation and depreciation) increased by 14% La1,032 crore, 32.5%activity with favitda margin.
The company’s management expects the margin to remain constant in 26 financial years.
India business has grown 11% La1,811 Crore performed better in key treatments.
Read also: Jews, weight loss drugs as the greatest opportunity in India
“We expect the Indian business to continue to perform better than market growth. Throughout the year, the focus will continue to increase market share, new launch performance, extended sections and regions in focus therapies throughout the year.”
As of August 1, Mehta will play the role of General Manager at Torrent Pharmaceuticals. He was interested in the company’s largest income contribution to Torrent Pharma’s India Business and in the integration of Unichem Laboratoies Ltd, which was purchased in 2017 and Curatio Healthcare Pvt. Ltd. In 2022.
The company saw that Brazilian business revenues increased by 11% La218 Crore.
JB Pharma acquisition to increase India game
Torrent is currently in the process of purchasing a control with a control at Drugmaker JB Chemicals and Pharmicals (JB Pharma) from the global investment company KKR. The agreement, which was announced in late June, values JB chemicals in equity valuation La25,689 Crore. The agreement will monitor the agreement.
The agreement will strengthen Torrent’s presence in the Indian market and launch it from the seventh position to the country’s fifth largest pharmaceutical company. It will also facilitate the entry into the rapidly growing contract development and production (CDMO) segment.
The management said the company is currently expecting a decision from the Indian Competition Commission (CCI) on the agreement.
